The levels of heparin left in the processed blood are negligible, when transfused back to the patient the systemic levels are within the same scope as levels needing to be achieved when heparin is administered, it is therefore not necessary… Read more »
Hemosep is best suited to elective producers where a steady blood loss occurs; in cases of massive trauma many centres will adopt the practice of returning the whole blood to the patient in order to give the blood back as… Read more »
The WBC are in a non-activated state therefore classed as fresh WBC’s, these are essential to fighting infections in the body and should therefore aid in the overall recovery period.
Hemosep will remove the amniotic fluid there is however considerable contamination residing in the fluid to which further research is needed to fully establish what contaminants can and cannot be removed.
The Hemosep device will remove the majority of the heparin solution on processing of 1 litre of blood there is no need to administer any protamine to offset this due to the overall systemic levels residing in the patient after… Read more »
If plasma free haemoglobin is being referred to, then there is no issue. We have not detected any significant levels of haemolysis with this device.
The blood product returned after concentration is very similar to that of the pre-surgical blood.
Due to the way Hemosep recycles the cell species, it saves money by reducing the need to add platelets to a patient (the cost of platelets are £209.30 per bag with an average 1.2 bags being used per patient transfusion). Hemosep… Read more »
The Hemosep device recycles all the cell species, therefore reducing the need for additional blood components to be added. In overall costs this makes using Hemosep one of the most cost efficient methods on the market.
Advancis Surgical will be developing additions to the device for use in the Orthopaedic, Paediatric and Neonatal practices.